Monte Rosa Therapeutics (GLUE) Other Accumulated Expenses (2020 - 2025)

Monte Rosa Therapeutics' Other Accumulated Expenses history runs 6 years deep, the most recent figure standing at $4.4 million for Q1 2025.

• On a quarterly basis, Other Accumulated Expenses rose 104.68% year-over-year to $4.4 million in Q1 2025; TTM through Mar 2025 was $4.4 million, a 104.68% increase from a year earlier, with the FY2024 full-year figure at $3.4 million, up 100.72% from the prior year.
• Other Accumulated Expenses rose to $4.4 million in Q1 2025 per GLUE's latest filing, from $3.4 million in the prior quarter.
• Across five years, Other Accumulated Expenses topped out at $5.0 million in Q4 2022 and bottomed at $840000.0 in Q4 2021.
• The 5-year median for Other Accumulated Expenses is $2.5 million (2023), against an average of $2.7 million.
• Across the five-year window, Other Accumulated Expenses soared 497.62% in 2022 and slumped 66.71% in 2023, its largest moves.
• Year by year, Other Accumulated Expenses stood at $840000.0 in 2021, then surged by 497.62% to $5.0 million in 2022, then slumped by 66.71% to $1.7 million in 2023, then surged by 100.72% to $3.4 million in 2024, then jumped by 31.81% to $4.4 million in 2025.
• Per Business Quant, the three latest GLUE Other Accumulated Expenses figures stand at $4.4 million (Q1 2025), $3.4 million (Q4 2024), and $1.3 million (Q3 2024).